EyeControl: Inspiring Communication Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

• Seed Funding: Approximately 2.5 million USD raised through equity and 150,000 USD from the European Commission Horizon 2020 grant. (Exhibit 4)
• Unit Economics: Estimated retail price of 2,500 USD per unit. Manufacturing cost estimated at 600 USD per unit. (Paragraph 12)
• Burn Rate: Monthly operational expenses estimated at 80,000 USD, primarily driven by R and D and clinical trial costs. (Paragraph 14)
• Market Size: Global ALS market estimated at 450,000 patients; ICU market includes 5 million ventilated patients annually in the US alone. (Exhibit 2)

Operational Facts

• Product Specifications: Wearable, screen-less eye-tracking device using infrared cameras and bone-conduction audio feedback. (Paragraph 5)
• Regulatory Status: CE Mark obtained for European markets. FDA Class II clearance pending. (Paragraph 18)
• Headcount: 15 full-time employees located in Tel Aviv, Israel, focused on software engineering and clinical coordination. (Paragraph 20)
• Distribution: Currently utilizing a direct-to-consumer model via the company website and limited partnerships with ALS advocacy groups. (Paragraph 22)

Stakeholder Positions

• Or Retzkin (CEO): Advocates for rapid global scaling and expansion into the ICU market to ensure financial sustainability. (Paragraph 3)
• Shay Rishoni (Co-founder and ALS Patient): Prioritizes accessibility for the locked-in community and maintaining the social mission. (Paragraph 4)
• Health Insurers: Demand longitudinal clinical data proving cost-savings in ICU length-of-stay before granting reimbursement codes. (Paragraph 25)
• ICU Nursing Staff: Express concern regarding the time required to calibrate devices for temporary patients. (Paragraph 27)

Information Gaps

• Customer Acquisition Cost (CAC): The case does not specify the cost to acquire a single B2C user versus a B2B hospital contract.
• Competitor Pricing: Precise pricing for screen-based competitors like Tobii Dynavox in the institutional segment is absent.
• Manufacturing Scalability: Data on the ability of the current supply chain to move from hundreds to thousands of units monthly is missing.

2. Strategic Analysis

Core Strategic Question

• EyeControl must decide whether to remain a specialized assistive technology provider for the ALS community or pivot to a high-volume medical device company serving intensive care units (ICUs).

Structural Analysis

Applying the Value Chain lens reveals that the primary bottleneck is not technology but distribution and reimbursement. In the B2C ALS market, the company faces fragmented buyers and high support costs. In the B2B ICU market, the buyer is concentrated, but the evidentiary hurdle for clinical efficacy is significantly higher. The current screen-less technology provides a cost advantage of 70 percent over traditional eye-tracking hardware, but this advantage is only defensible if EyeControl secures institutional lock-in before incumbents miniaturize their own hardware.

Strategic Options

Option 1: Institutional ICU Pivot. Shift all sales and marketing resources to target hospital systems. This requires 12 to 18 months of clinical trials to prove reduced ICU stays.

• Rationale: High volume, recurring revenue through disposable components, and clear clinical value.
• Trade-offs: Requires significant capital for trials and neglects the founding social mission.

Option 2: Hybrid B2C and B2B Model. Maintain the ALS consumer line while piloting in small clinics.

• Rationale: Preserves the brand and provides immediate cash flow.
• Trade-offs: Risks organizational distraction and fails to achieve the scale needed for profitability.

Preliminary Recommendation

EyeControl should pursue the Institutional ICU Pivot. The ALS market is too small to support the R and D overhead required for a sophisticated AI platform. The ICU market offers a path to 50 million USD in annual recurring revenue within five years, provided the company secures FDA clearance and proves that eye-communication reduces sedation time for ventilated patients.

3. Implementation Planning

Critical Path

• Month 1-4: Finalize FDA Class II submission and launch a 100-patient clinical study in two US-based ICUs to measure sedation reduction.
• Month 5-8: Recruit a US-based Head of Sales with experience in hospital procurement and medical device reimbursement.
• Month 9-12: Transition manufacturing to a contract partner capable of 5,000 units per month and secure a dedicated HCPCS reimbursement code.

Key Constraints

• Regulatory Latency: Any delay in FDA approval will exhaust the remaining 1.2 million USD in cash reserves before the ICU pilot concludes.
• Clinical Evidence: If the study fails to show a statistically significant reduction in ICU length-of-stay, hospital CFOs will reject the 2,500 USD per unit cost.

Risk-Adjusted Implementation Strategy

The company must adopt a phased rollout. Phase one involves leasing the devices to hospitals rather than selling them outright. This lowers the initial barrier to entry for procurement departments. Contingency planning includes a bridge financing round of 1.5 million USD in month six if the FDA review enters a second cycle of inquiries. Success depends on the technology moving from a communication tool to a diagnostic and monitoring tool for medical staff.

4. Executive Review and BLUF

BLUF

EyeControl must pivot immediately to the ICU institutional market. The ALS patient segment, while central to the company origin, lacks the scale to sustain a venture-backed growth trajectory. By focusing on ventilated ICU patients, the company addresses a market 50 times larger and positions its technology as a clinical necessity rather than a social aid. Success requires securing FDA Class II clearance and proving that eye-tracking reduces ICU sedation costs. The current cash position allows for one clinical trial cycle; execution must be flawless to avoid insolvency within 14 months. APPROVED FOR LEADERSHIP REVIEW.

Dangerous Assumption

The analysis assumes that ICU nurses will integrate a new wearable into their workflow. Hospital staff are chronically overstretched. If the device adds even five minutes of setup time per shift, adoption will fail regardless of the clinical benefits to the patient.

Unaddressed Risks

• Incumbent Response: Tobii Dynavox has deeper pockets and existing hospital relationships. They can price EyeControl out of the market if they perceive the ICU pivot as a threat. (Probability: High; Consequence: Severe)
• Cybersecurity: As a wearable connected to hospital networks, any data breach involving patient eye-movement data would result in catastrophic liability. (Probability: Moderate; Consequence: Severe)

Unconsidered Alternative

The team failed to consider licensing the core eye-tracking AI to existing ventilator manufacturers. This would eliminate the need for a dedicated sales force and manufacturing overhead. While it reduces the potential for a high-multiple exit, it guarantees immediate market penetration and removes the regulatory burden from EyeControl.

MECE Analysis

• Market Segmentation: Chronic Care (ALS/Locked-in) vs. Acute Care (ICU/Ventilated).
• Revenue Streams: Hardware Sales vs. Disposable Components vs. Software Licensing.
• Geographies: European Union (CE Mark) vs. North America (FDA Pending).